Review Sheds Light on Genetic Testing in Patients With Metastatic Prostate Cancer

home / oncclub / review-sheds-light-on-genetic-testing-in-patients-with-metastatic-prostate-cancer

Kara N. Maxwell, MD, PhD, discusses data from a review published in JAMA Oncology which found that despite BRCA mutations being known actionable alterations, genetic testing rates for these aberrations are significantly lower in males compared with females.

Kara N. Maxwell, MD, PhD

Comparable Germline Variant Rates Seen Across Racial Groups in Metastatic Prostate Cancer

April 26th 2024

Kara N. Maxwell, MD, PhD, discusses the prevalence of germline mutations in racially diverse cohorts of patients with metastatic prostate cancer.

Kara N. Maxwell, MD, PhD

Dr Maxwell on Cancer Risk for Males Carrying Germline BRCA Mutations

August 9th 2024

Kara N. Maxwell, MD, PhD, discusses the risk of cancer for males carrying BRCA mutations.

Kara N. Maxwell, MD, PhD, director, Men and BRCA Program, Basser Center, associate professor, medicine (hematology-oncology), Perelman School of Medicine, University of Pennsylvania

Review Highlights the Need to Increase Germline BRCA Mutation Testing in Males

August 12th 2024

Kara N. Maxwell, MD, PhD, discusses the need to improve genetic testing rates for BRCA mutations in the male population.